

# *HJERNEKRÆFT – MOD BEDRE BEHANDLINGER*

# TAK

---



**Kræftens Bekæmpelse**



Danish Comprehensive Cancer Center

# BAGGRUND

---

Ca. 250-300 patienter årligt i DK


**Uhelbredelig** med kort forventet levetid

**Forringet livskvalitet**

- lammelse, træthed, epilepsi, forstyrrelse af sprog, tænkning og personlighed)

**Hård behandling**



- Operation – Kemo – Stråler



# FRA FORSKNING TIL BEHANDLING


**Anvendt forskning**  
Fra laboratorie til  
praksis

**Behandling**  
Sikre og effektive  
hjerneoperationer





# FORSKNING

## Elektrisk kræftbehandling med TFields



## Menneskehjernens fysiologi




## Kunstig intelligens



### Intraoperative digital biopsy



### Preoperative MRI



# TUMOR TREATING FIELDS

JAMA Network™

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma  
A Randomized Clinical Trial


Roger Stupp, MD<sup>1,2,3</sup>, Sophie Taillibert, MD<sup>4</sup>, Andrew Kanner, MD<sup>5</sup>, et al

> Author Affiliations




JAMA. 2017;318(23):2306-2316. doi:10.1001/jama.2017.18718



**B** Overall survival






## Software til dosisbestemmelse




## Anvendelse

### Karakterisering og planlægning




### Udvikling af ny og bedre anvendelse


Før



Kirurgi




Efter



# KLINISK AFPRØVNING

## Fase 1



15 patienter med tilbagefald  
(afsluttet 2019)

Aarhus Universitetshospital

**Konklusion:**  
Sikkert og sandsynligt effektivt

**Neuro-Oncology Advances**

2(1), 1–11, 2020 | doi:10.1093/noajnl/vdaa121 | Advance Access date 15 September 2020

**OptimalTTF-1: Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma**

## Fase 2

### Design

Nationalt lodtrækningsforsøg (2020-2024).

### Formål

At bestemme effekten ved forsøget.

### Status



7 patienter inkluderet ud af 52/83

### Sponsor

AUH (Anders Korshøj)


### Koordinerende Investigator

Læge, PhD stud Nikola Mikic





# MENNESKERNE BAG



# HVAD BETYDER NOGET FOR PATIENTERNE?

---



HJERNETUMORFORENINGEN  
hjermetumorforeningen.dk

*Tak til medlemmer, bestyrelse, frivillige, mm*

# TAK TIL KB OG DCCC



Kræftens Bekæmpelse



Danish Comprehensive Cancer Center

## The DCCC Brain Tumor Center


The Research Center is a member of DCCC and supported by The Danish Cancer Society



*Klinikchef, Prof.  
Ulrik Lassen, RH*



*Prof, overlæge  
Hans S. Poulsen  
RH*



**Formål**  
*At forlænge overlevelsen for  
patienter med hjernekræft*

**Fra grundvidenskab  
til klinisk forskning**

# TAK TIL BIDRAGYDERE

---



Kræftens Bekæmpelse



AARHUS UNIVERSITY



DANMARKS FRIE  
FORSKNINGSFOND

novocure®

# TAK FOR OPMÆRKSOMHEDEN

---



*Gorm von Oettingen  
Ledn. Overlæge, AUH*



*Jens Chr. H. Sørensen  
Professor, AUH*



AARHUS UNIVERSITY



novocure®